Shots:
- The company reported the new data from the P-I COVID-19 trial evaluating the safety & immunogenicity of VXA-CoV2-1 suggesting that vaccine triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins and has broad cross-coronavirus activity
- The results showed higher CD8+ T-cell responses as measured by IFN-g and TNF-a induction than the patients vaccinated with Pfizer and Moderna’s vaccines
- The Vaxart vaccine candidate elicited a T-cell response against SARS-Cov-2, as well as showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43
Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Vaxart
The post Vaxart Reports News Data of VXA-CoV2-1 (Oral COVID-19 Vaccine) in P-I Trial Against Other Coronaviruses first appeared on PharmaShots.
